FDAMA 114 and the 21st Century Cures Act

By Xcenda

Xcenda presented an educational symposium on FDAMA 114 and the 21st Century Cures Act at ISPOR's 22nd International Meeting in Boston on May 23, 2017. Jay Jackson, PharmD, MPH, moderated a panel of experts to discuss insights from US payers and pharmaceutical manufacturers on the implications of the 21st Century Cures Act on the exchange of HCEI.

Related Content

Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers

Jennifer Snow, MPH
August 2017

Health disparities and health technology assessment: Current value assessment frameworks fall short

Xcenda
August 2021
Hands holding coins

Gaining real-world oncology insights from engagement of key opinion leaders through virtual and live solutions

Xcenda
August 2021
Insights written in the sky